Computed Tomography (CT)-Guided Biopsy Market Report 2026

The computed tomography (CT)-guided biopsy market size has grown strongly in recent years. It will grow from $0.77 billion in 2025 to $0.82 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising global cancer incidence, increasing adoption of imaging-based diagnostics, expansion of hospital radiology infrastructure, growing preference for minimally invasive procedures, improved availability of ct imaging systems.

The computed tomography (CT)-guided biopsy market size is expected to see strong growth in the next few years. It will grow to $1.06 billion by 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing demand for early-stage cancer detection, rising adoption of precision medicine-based diagnostics, expansion of outpatient diagnostic centers, growing aging population requiring diagnostic interventions, advancements in biopsy needle technologies and procedural safety. Major trends in the forecast period include increasing adoption of minimally invasive diagnostic procedures for early and accurate disease detection, rising demand for image-guided precision interventions in oncology and infection diagnosis, growing preference for outpatient and ambulatory biopsy procedures to reduce hospital burden, expansion of interventional radiology departments improving access to ct-guided procedures, increasing focus on early cancer screening and tissue-based diagnostics in clinical workflows.

The increasing incidence of cancer is expected to propel the growth of the CT-guided biopsy market going forward. The rise in cancer cases is primarily contributing to market expansion, driven by an expanding aging population, as older individuals face a higher risk of developing solid tumors that require accurate and timely diagnostic confirmation. CT-guided biopsy supports this requirement by enabling precise tissue sampling from deep-seated or anatomically complex lesions, particularly in organs such as the lung, liver, pancreas, kidney, and bone, where imaging alone is often insufficient for definitive diagnosis and treatment planning. For instance, in April 2024, according to the International Agency for Research on Cancer, a France-based intergovernmental organization forming part of the World Health Organization, there were approximately 20 million new cancer cases and nearly 10 million cancer-related deaths globally in 2022. Demographic projections indicate that the annual number of new cancer cases is expected to reach 35 million by 2050, representing a 77% increase compared to 2022. Therefore, the rising incidence of cancer is supporting and propelling the growth of the CT-guided biopsy market.

Leading companies operating in the CT-guided biopsy market are focusing on the development of advanced navigation technologies, such as real-time CT navigation systems, to enhance procedural accuracy, reduce radiation exposure, and improve workflow efficiency. Real-time CT navigation systems are integrated imaging and guidance platforms that utilize 3D visualization and electromagnetic tracking to assist clinicians in accurately guiding biopsy needles to target lesions while minimizing the need for repeated imaging. For example, in April 2023, GE HealthCare, a US-based medical technology company, introduced its CT-Navigation solution. The system provides real-time 3D CT imaging for stereotactic needle guidance across procedures such as biopsies, ablations, and drainage. It incorporates electromagnetic navigation technology that enables complex needle trajectories, allowing clinicians to avoid critical anatomical structures. Additionally, the solution reduces radiation dose and procedure time by minimizing the need for multiple control scans while improving targeting accuracy, thereby enhancing safety and efficiency in interventional procedures.

In April 2023, GE HealthCare, a United States-based medical technology company, acquired IMACTIS for an undisclosed amount. Through this acquisition, GE HealthCare enhanced its interventional guidance capabilities by integrating CT-based needle navigation technology to improve procedural accuracy, workflow efficiency, and radiation management. IMACTIS is a France-based provider of CT-guided interventional navigation solutions for minimally invasive procedures.

Major companies operating in the computed tomography (ct)-guided biopsy market are Samsung Electronics, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Stryker Corporation, Medtronic PLC, Boston Scientific Inc., Becton Dickinson and Company, Siemens Healthineers, Agilent Technologies Inc., GE HealthCare Technologies, Canon Inc., Zimmer Biomet Holdings Inc., Terumo Corporation, Fujifilm Corporation, Illumina Inc., Koninklijke Philips N. V., Olympus Corporation, Hologic Inc., Teleflex Incorporated, Sysmex Corporation, QIAGEN N. V., Bio-Rad Laboratories Inc., Shimadzu Corporation, Merit Medical Systems Inc., Guerbet (GBT. PA)

North America was the largest region in the CT-guided biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the computed tomography (CT)-guided biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the computed tomography (CT)-guided biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The CT-guided biopsy market includes revenues earned by entities by providing services such as ultrasound-guided biopsy, MRI-guided biopsy, stereotactic biopsy, fluoroscopy-guided biopsy, image-guided fine needle aspiration, core needle biopsy services, and interventional radiology biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.